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The positive effect on ketamine as a priming adjuvant in
antidepressant treatment
A Melo1,2, N Kokras3, C Dalla3, C Ferreira1,2, AP Ventura-Silva1,2, N Sousa1,2 and JM Pêgo1,2
Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine observed in preclinical and
clinical research makes it a promising therapeutic to improve current major depression (MD) treatment. Our work intended to
evaluate whether the combined use of classic antidepressants (imipramine or ﬂuoxetine) and ketamine would improve the
antidepressant response. Using an animal model of depressive-like behavior, we show that the addition of ketamine to
antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of
antidepressants alone. In conclusion, our results suggest the need for a reappraisal of the current pharmacological treatment of MD.
Translational Psychiatry (2015) 5, e573; doi:10.1038/tp.2015.66; published online 26 May 2015
INTRODUCTION
Major depression (MD) is a highly incident and prevalent multi-
factorial disease responsible for great personal and socioeconomic
burden.1 Currently used therapeutic regimens have important
limitations such as long-time lag for clinical response, induction of
resistance or even response failure.2,3 Several different factors
seem to have a role in MD: imbalances in neurotransmitters4 and
cytokine production,5,6 hypothalamic–pituitary–adrenal axis
dysregulation7 and impaired neuroplasticity.8,9
Currently used antidepressants target the metabolism/transport
of monoaminergic neurotransmitters, such as serotonine and
noradrenaline. However studies show that glutamate (GLU)
deregulation is also implicated in MD.10,11 The use of N-methyl-
D-aspartate (NMDA) receptor antagonists as antidepressants is a
relatively new concept.12 Ketamine (KET), an NMDA antagonist,
was observed to induce a rapid antidepressant action in MD
patients,13 even in those considered treatment resistant.14,15 The
rapid antidepressant effect of KET has also been described in
animal models of depressive-like behavior.16,17 Such an effective
drug promises to be an important therapeutic tool to improve MD
treatment efﬁcacy but, surprisingly, studies where classic anti-
depressants are used in combination with NMDA antagonists are
scarce. Therefore, herein we assessed whether the use of an acute
KET treatment could improve the efﬁcacy and/or anticipate the
clinical effect of both tricyclic antidepressants and selective
serotonin reuptake inhibitor agents in a rat model of depression.
MATERIALS AND METHODS
Animals
Male Wistar rats (Charles River Laboratories, Barcelona, Spain), aged
3 months were housed (three per cage) under standard laboratory
conditions (12 h light: 12 h dark cycle, at 22 °C, relative humidity of 55%;
free access to food and water). Eighty-four animals were used. Animals
initially performed the determination of the baseline value of sucrose
consumption test (SCT) and then were randomly assigned to the following
experimental groups—a control group without stress exposure and six
groups exposed to unpredictable chronic mild stress (uCMS). After 4 weeks
used to establish a depressive-like behavior phenotype, uCMS-exposed
animals were randomly assigned to six different groups: one untreated
group (i) uCMS, and the other ﬁve experimental groups according to the
assigned treatment: (ii) imipramine, (iii) ﬂuoxetine, (iv) KET alone for the
ﬁrst 3 days and saline for the remainder period (uCMS-KET), or treated with
KET daily for 3 days and either (v) FLX (KET-FLX) or (vi) IMP (KET-IMP) for
the remaining treatment period (n=12 per group; Figure 1).
Behavioral tests were conducted during the diurnal phase, between
1000 and 1800 h. Animals were euthanized 24 h after performing the last
behavioral evaluation and brains processed for neurochemical and
structural analysis. All the procedures were carried out in accordance with
the Animal Ethics Committee of the Portuguese National Veterinary
Directorate and with the guidelines for the care and handling of laboratory
animals in the Directive 2010/63/EU of the European Parliament.
Unpredictable chronic mild stress
A modiﬁed version of an uCMS protocol18 was used to establish the animal
model of depressive-like behavior. It consisted of chronic exposure to
unpredictable mild stressors (conﬁnement to a restricted space for 1 h,
placement in a tilted cage (30 °) for 3 h, housing on damp bedding for 8 h,
overnight illumination, 18 h food deprivation followed by exposure to
inaccessible food for 1 h, water deprivation for 18 h followed by exposure
to an empty bottle for 1 h, and reversed light/dark cycle for 48 h every
7 days) until establishment of the model phenotype and then through the
duration of behavioral evaluation.
Antidepressant treatment
After establishment of depressive-like behavior, uCMS animals were
treated according to the assigned group with daily intraperitoneal
injections of saline, FLX (10 mg kg− 1, Kemprotec, Cumbria, UK), IMP (10 -
mg kg− 1, Sigma-Aldrich, St. Louis, MO, USA) and KET (10 mg kg− 1, Pﬁzer,
New York, NY, USA) with 0.9% saline as vehicle for 14 days and then
performed behavioral evaluation. Treatment and administration scheme
were chosen on the basis of their therapeutic effects in previous
studies.8,19
KET is a general anesthetic with psychomimetic characteristics and has
been used to induce psychotic trait in animal models of schizophrenia. To
rule out that the dosage-induced phenotypic changes related no animal
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models of schizophrenia, we assessed locomotor activity in the open ﬁeld
and sensorimotor gating in the pre-pulse inhibition (PPI).
Behavioral analysis
All animals (controls and uCMS-exposed) were submitted to a series of
behavioral testing. Sucrose preference tests were performed weekly over
the 6 weeks of exposure to uCMS. The remainder tests (elevated-plus
maze, forced-swim test and open ﬁeld) were performed after 14 days of
treatment (Figure 1).
Sucrose consumption test
Anhedonia was assessed weekly during exposure to uCMS using the SCT.
Brieﬂy, animals were allowed to habituate to the sucrose solution for
1 week before the uCMS protocol to establish baseline preference levels.
To test sucrose preference, animals that were food- and water-deprived for
18 h were presented with two pre-weighed bottles containing 1% sucrose
solution or tap water for a period of 1 h. Sucrose preference was calculated
according to the formula: sucrose preference= (sucrose intake/(sucrose
intake+water intake)) × 100, as previously described.8 Anhedonia was
deﬁned as a reduction in sucrose preference.
Elevated-plus maze
To assess anxiety-like behavior, animals were tested on an elevated-plus
maze (MED-NIRPMNR; Med Associates, St Albans, VT, USA) as previously
described.20 Animals were placed in the central junction facing an open
arm, and allowed to explore for 5 min. Entry was deﬁned as all four paws
being positioned within one arm. The test was recorded and the ratio
between time in open arms and time in closed arms was measured.
Activity in the open arms was calculated as open arm entries percentage
(entries into the open arms/total entries into all arms) and time spent in
open arm percentage (time spent in the open arms/total time spent in all
arms). The degree of anxiety was indirectly related to the time spent in the
open arms and the number of open arm entries.
Forced-swim test
Learned helplessness was evaluated in the forced-swim test on the last day
of exposure to uCMS. Twenty-four hours after a pre-test session (10 min),
rats were placed in cylinders ﬁlled with water (25 °C; depth 30 cm) for a
period of 5 min. Test sessions were assessed using a camera connected to
a video tracking system (Viewpoint, Lyon, France); the system automati-
cally calculated immobility time and latency to immobility. Learned
Figure 1. Diagram with experiment protocol. Complete experiment protocol (a); treatment period and behavioral evaluation (b). EPM,
elevated-plus maze; FST, forced-swim test; OF, open ﬁeld; SPT, sucrose preference test; uCMS, unpredictable chronic mild stress.
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helplessness behavior was deﬁned as an increase in time of immobility and
a decrease in latency to immobility.
Open ﬁeld
To assess locomotor activity, rats were placed in an open-ﬁeld apparatus
(43.2 (length) × 43.2 (width) × 30.5 (height) cm, transparent acrylic walls
and white ﬂoor, Med Associates) in a room illuminated by white light.
Instant position was monitored over a period of 5 min by an array of two
16 beam infrared arrays. Total distance and average speed was used as a
measure of locomotor activity.
Pre-pulse inhibition
An additional setting of animals was used to evaluate KET safety regarding
induction of PPI impairment. Startle reﬂexes were measured in two
identical startle response systems (SR-LAB, San Diego Instruments, San
Diego, CA, USA), each consisting of a non-restrictive Plexiglas cylinder
(8.8 (internal diameter) cm, 22.2 (length) cm), mounted on a Plexiglas
platform and placed in a ventilated, sound-attenuated chamber. Cylinder
movements were detected and measured by a piezoelectric element
mounted under each cylinder. A dynamic calibration system (San Diego
Instruments) was used to ensure comparable startle magnitudes across the
two devices. Startle stimuli were presented through a high frequency
speaker located 33 cm above the startle chambers. Startle magnitudes
were sampled each millisecond (ms) during a period of 200 ms beginning
at the onset of the startle stimulus. A startle response is deﬁned as the
peak response during this 200-ms period. Animals were habituated to the
apparatus 5min daily 2 days before the testing period. After the
habituation period, rats were taken from their home cage and placed in
the test chamber. The chamber was then sealed and each animal allowed
to acclimatize to the startle chamber for a period of 5 min. In addition,
background white noise, with an intensity of 63 dB, was maintained to
minimize the impact of acoustic stimuli outside the chamber environment.
Following ﬁve introductory 120-dB startle trials (noise lasting 40ms), a total
of 35 test trials were pseudo-randomly delivered as follows: (a) ﬁve trials
with background noise only, (b) 10 startle trials of 120 dB and (c) ﬁve pre-
pulses of each of four different intensities preceding a startle trial. Pre-
pulse intensities of 2, 4, 8 and 16 dB above the background noise level
lasted 20ms and preceded the 120-dB startle presentation in 100ms. Inter-
trial intervals ranged from 10 to 20 s. The average startle response was
assessed in the 100-ms period following the onset of the startle stimulus
presentation.
Neurochemical analysis
Monoamines levels were measured using high performance liquid
chromatography (HPLC), combined with electrochemical detection.
From each experimental group, seven rats were killed by decapitation.
After decapitation, the animal heads were snap-frozen in liquid nitrogen
to prevent tissue degradation. The brains were quickly extracted and
placed in an icy surface; under a stereomicroscope the prefrontal
cortex (PFC), dorsal hippocampus, ventral hippocampus and nucleus
accumbens (NAc) were dissected. The dissected tissues were weighed and
then homogenized and deproteinized in 100 μl of 0.2 N perchloric acid
solution (Applichem, Darmstadt, Germany) containing 7.9 mM Na2S2O5
and 91.3 mM Na2-EDTA (Riedel-de Haën, Seelze, Germany), centrifuged
at 15 000 r.p.m. for 45min at 4 °C and the supernatant stored at − 80 °C
until analysis.
The analytical measurements were performed using a GBC LC1150 (GBC,
Braeside, VIC, Australia) HPLC pump coupled with a BAS LC4C (Bioanalytical
Systems, West Lafayette, IN, USA) electrochemical detector and pre-column
derivatization as described previously.21 The working electrode was glassy
carbon, the reference electrode was Ag/AgCl and the columns used were
ODS Hypersil, 250mm×4.6 mm, 5 μm (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). The voltage of the working electrode was set at +800mV in the
LC4C amperometric detector and the ﬂow rate of the LC1150 HPLC pump
was set at 1.0 ml min− 1. The mobile phase consisted of an acetonitrile
(Merck, New York, NY, USA): 100mM phosphate buffer (5:95) pH 4.9,
containing 50 μM Na2-EDTA (Riedel-de Haën). Samples were initially diluted
1:5 with ddH2O, then further diluted 1:1 with 0.1 M Borax buffer (Sigma-
Aldrich), pH 9.6. o-Phthalaldehyde (Sigma-Aldrich) was subsequently
added and left to react at room temperature for 10min before injection.
Quantiﬁcation of GLU and aspartate (ASP) was done by comparison of the
area under the curve with that of reference external standards using HPLC
software (Clarity, Data-Apex, Prague, Czech Republic), as previously
described.22,23
Histological procedures
After the end of behavioral evaluation, ﬁve rats from each group were
perfused transcardially with saline (NaCl 0.9%) under deep pentobarbital
anesthesia. Brains were removed and kept in Golgi-Cox solution for
15 days and then transferred to a 30% sucrose solution for 5 days. Sections
(200 μm) were obtained using a vibratome and collected in 6% sucrose
and blotted dry onto gelatin-coated microscope slides. They were
alkalinized in 18.7% ammonia, developed in Dektol (Kodak, Rochester,
NY, USA), ﬁxed in Kodak Rapid Fix, dehydrated and xylene-cleared before
coverslipping. Dendritic arborization and spine numbers were analyzed in
layer II/III of infralimbic (IL) area of PFC, and dentate gyrus and CA3 region
of hippocampus. Selected neurons had every branch of the dendritic tree
reconstructed at × 1000 (oil) magniﬁcation using a motorized microscope
(Axioplan 2; Carl Zeiss, Jena, Germany) and Neurolucida software
(Microbrightﬁeld, Williston, VT, USA) and three-dimensional analysis of
the reconstructed neurons was performed using NeuroExplorer software
(Microbrightﬁeld). For each animal, 20 neurons were studied and
measurements from individual neurons from each animal were averaged.
The following dendritic morphology parameters were examined: dendritic
length and the number of primary dendrites and dendritic branching
points were compared across experimental groups; dendritic spines were
assessed according to their morphology mushroom-shaped, thin, thick and
ramiﬁed spines and dendritic spine density (number of spines/dendritic
length) and the proportion of spines in each category was calculated for
each neuron in branches that were either parallel or at acute angles to the
coronal surface of the section. In dentate granule cells, proximal and distal
branches were analyzed for each neuron; basal branches and proximal and
distal apical branches in pyramidal neurons in the CA3 region and IL area
of the PFC were analyzed. Neuronal reconstructions were masked to the
observer.
Statistical analysis
Sample size was determined considering a medium effect size (f= 0.25), a
type I error α= 0.05 and a statistical power (1—type II error) of 0.8, and also
the performance of HPLC and Golgi analysis after behavioral analysis, with
the need to establish two diferent groups of animals. In practice, we ended
up using a total of 84 animals, with n= 12 to each experimental group.
During the experiment, we performed three moments of randomization:
the ﬁrst one after the establishment of a baseline in SCT, the second one
after establishment of the uCMS phenotype, and the last one after
behavioral evaluation to establish two separate groups to perform either
HPLC or neurostructural analysis.
We used masking of the experimental group assignment to all animal/
samples during performance and analysis of behavior tests, HPLC and
structural Golgi analysis.
Data obtained in experiment were analyzed applying analysis of
variance. Quantitative data obtained for parameters analyzed regarding
elevated-plus maze, forced-swim test, open ﬁeld, PPI, neuronal dendritic
architecture and HPLC measurements were analyzed using one-way
analysis of variance, and whenever appropriate, post hoc comparisons
between experimental groups were performed using Bonferroni’s test. For
data obtained in the SCT, we used repeated measures analysis of variance.
Sphericity assumption and homogeneity of group variances were veriﬁed
and statistical analyses were made accordingly. During statistical analysis,
we did not perform any data transformation. All data are presented as
means± s.e.m. In all cases, statistical signiﬁcance was set at P⩽ 0.05 (two-
sided). Statistical analysis was performed using IBM SPSS statistics 20.0
(IBM, Armonk, NY, USA).
RESULTS
Behavioral data
To evaluate hedonic behavior, the SCT was performed weekly
during the establishment of the depressive-like behavior and
during the treatment period. After 4 weeks of exposure to uCMS,
animals developed a signiﬁcant difference in sucrose preference
compared with control animals (Po0.05). On the seventh day of
treatment, animals treated with KET (Po0.05), FLX-KET (Po0.05)
and IMP-KET (Po0.05) animals (F6,77 = 4.179, Po0.01), but not the
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remaining treated groups had reversion of anhedonic phenotype
(Figure 2b). On the 14th day, all animals treated with antidepres-
sant display behavioral rescuing of anhedonic behavior (IMP
(Po0.01) and FLX (Po0.05), IMP-KET (Po0.001) and FLX-KET
(Po0.001)), except for those given only KET that did not display
any longer the behavioral rescuing effect detected 1 week before
(F6,77 = 10.50, Po0.001; Figure 2c). In animals given FLX, when KET
was added (FLX-KET) there was a signiﬁcantly higher sucrose
preference at 14th day when compared with animals given FLX
alone (Figures 2a and c).
In the forced-swim test, uCMS animals showed decreased
latency to immobility time (F6,77 = 7.912, Po0.001) and increased
immobility time (F6,77 = 11.00, Po0.01) when compared with
control animals. Comparing with uCMS, all treated animals
showed a signiﬁcantly increased latency to immobility: FLX, KET
(Po0.05), IMP (Po0.01) and IMP-KET, FLX-KET (Po0.001;
Figure 3a); and also a signiﬁcant decrease in immobility time:
IMP, FLX (Po0.05) and IMP-KET, FLX-KET (Po0.01; Figure 3b). In
latency to immobility time, the addition of KET to those animals
treated as well with FLX induced a signiﬁcant beneﬁcial effect.
Figure 2. Ketamine effect in the reversion of anhedonic phenotype. Effect of uCMS in sucrose preference (a). Reversion of anhedonic
phenotype at the end of ﬁrst week of treatment in KET, FLX-KET and IMP-KET (Po0.05) (b); rescue of anhedonic behavior by the end of second
week of treatment in all animals treated with antidepressant and the addition of KET produces a signiﬁcantly higher sucrose preference by the
end of the second week when comparing the group FLX-KET with FLX (Po0.05) (c). FLX, ﬂuoxetine; IMP, imipramine; KET, ketamine; uCMS,
unpredictable chronic mild stress. Mean± s.e.m., n= 12, *Po0.05; **Po0.01; ***Po0.001.
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In the elevated-plus maze test, uCMS animals displayed an
anxious phenotype, spending signiﬁcantly less time exploring
open arms than control animals (F6,77 = 3.111, Po0.001); both
IMP-KET (Po0.05) and FLX-KET (Po0.01) groups showed a
signiﬁcant increase in time spent in open arms when compared
with uCMS animals; no other signiﬁcant differences were found
(Figure 3c). Regarding the number of entries in open arms, control
animals showed a signiﬁcantly higher number than untreated
uCMS group (F6,77 = 11.05, Po0.001) and both FLX (Po0.01) and
IMP-KET, FLX-KET (both Po0.001) also have signiﬁcantly higher
entries in open arms (Figure 3d).
No signiﬁcant effects of uCMS or pharmacologic treatment were
found concerning locomotory activity, as evaluated in the open-
ﬁeld test (data not shown). Treatment with KET, in the dosage
used in our experimental protocol, failed to show PPI disruption
(data not shown).
Neurotransmitter proﬁle
In MD, therapy is still largely based on the ‘monoaminergic
hypothesis’, which is fundamentally associated with alterations in
the level of neurotransmitters. According to this and as an attempt
to investigate the possible mechanism underlying the effect of
giving KET together with antidepressants, the levels of neuro-
transmitters, more speciﬁcally GLU and ASP were analyzed by
HPLC. For that, important key areas for MD such as PFC and
hippocampus were selected. In addition, we have investigated the
levels of these neurotransmitters in additional brain areas, which
are related to the behavioral proﬁle of recovery, such as the NAc.
(Figure 4).
Taking into consideration the GLU levels, NAc was the only
stress-induced brain region that displayed a reduction in its levels
(F6,55 = 2.254, Po0.01). Treatment with antidepressants produced
an increase in GLU levels, but only IMP-KET and FLX-KET displayed
a signiﬁcant increase in GLU levels compared with untreated
animals (both Po0.01; Figure 4a).
Measurement of ASP levels showed no overall effect in PFC
(F6,55 =0.672, P=0.673; Figure 4f), dorsal hippocampus (F6,55 =1.397,
P=0.234; Figure 4g) and ventral hippocampus (F6,55= 1.143,
P=0.325; Figure 4h). Contrarily, in the NAc brain area, there was an
overall group effect (F6,55 =2.554, P=0.031); post hoc analysis showed
control animals have higher ASP than uCMS untreated animals
(F6,55 =2.261, Po0.05) and that uCMS-exposed animals treated with
IMP-KET and FLX-KET have signiﬁcantly higher ASP levels than
untreated uCMS animals (F6,55 =2.261, Po 0.05; Figure 4f).
Neuronal structural analysis
Given the neuroplastic action of antidepressants, we thought it to
be interesting to analyze dendritic architecture of neurons in these
areas. There is evidence that KET can induce rapid changes in
dendritic spine morphology, which may be relevant to the
antidepressant effect shown in the behavioral analysis. We focus
our attention in neurons from layers II/III of IL cortex in PFC,
pyramidal neurons from CA3 and granule neurons from the
hippocampus and medium spiny neurons from NAc.
Figure 3. Ketamine treatment effect in anxiety and learned helplessness. All treated animals showed a signiﬁcantly increased latency to
immobility: FLX, KET (Po0.05), IMP, (Po0.01) and IMP-KET, FLX-KET (Po0.001). The addition of KET caused a signiﬁcant increase in latency to
immobility time in FLX-KET against KET (a); signiﬁcant decrease in immobility time: IMP, FLX (Po0.05) and IMP-KET, FLX-KET (Po0.01) (b); IMP-
KET (Po0.05) and FLX-KET (Po0.01) groups with signiﬁcant increase in time spent in open arms when compared with uCMS animals (c); FLX
(Po0.005), IMP-KET (Po0.001) and FLX-KET (Po0.001) with signiﬁcant higher entries in open arms (d). FLX, ﬂuoxetine; IMP, imipramine; KET,
ketamine; uCMS, unpredictable chronic mild stress. Mean± s.e.m., n= 12, *Po0.05; **Po0.01; ***Po0.001.
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In the pyramidal neurons of the IL, uCMS induced atrophy in
basal and apical dendrites (F6,28 = 8.563, Po0.001; F6,28 = 4.074,
Po0.01). In basal dendrites, treatment with IMP-KET (Po0.01),
FLX (Po0.05) and FLX-KET (Po0.001) induced a reversion of
dendritic shortening. In the apical dendrites, all treated animals
(Po0.05) had a signiﬁcant recovery (Figures 5g and d).
In dentate gyrus granule cell dendrites, data conﬁrm a
signiﬁcant stress-induced atrophy (F6,28 = 7.103, Po0.05), which
Figure 4. Ketamine treatment induces changes in HPLC measured levels of (a–d) glutamate (GLU) and (e–h) aspartate. IMP-KET and FLX-KET
increase in GLU levels compared with untreated animals in NAc (both Po0.01) (a). Treatment in IMP-KET and FLX-KET increases aspartate
levels in PFC (Po 0.05) (f). FLX, ﬂuoxetine; IMP, imipramine; KET, ketamine; NAc, nucleus accumbens; PFC, prefrontal cortex. Mean± s.e.m.,
n= 7, *Po0.05; ***Po0.001.
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was recovered by the treatment with IMP-KET (Po0.001), IMP and
FLX-KET (both Po0.05). Animals treated with KET alone and FLX
alone did not show signiﬁcant changes in dendritic length
(Figure 5j).
Hippocampal CA3 pyramidal neurons basal (F6,28 = 33.28,
Po0.001) and apical (F6,28 = 17.93, Po0.01) dendrites show a
signiﬁcant decrease in their length in animals that were exposed
to uCMS. Treatment with KET (Po0.001), IMP-KET (Po0.001) and
FLX-KET (Po0.001) recovered basal dendritic length, whereas
FLX-KET was able to induce a signiﬁcant increase in basal dendritic
length compared with FLX alone (Po0.01). Neither IMP nor FLX
alone increased CA3 basal dendritic length signiﬁcantly when
compared with uCMS animals. Regarding the apical dendritic tree,
treatment with KET (Po0.01), IMP-KET (Po0.01), FLX alone
(Po0.01) and FLX-KET (Po0.01) induced recovery, whereas
treatment with IMP alone failed to increase CA3 apical dendritic
length signiﬁcantly. Both IMP-KET and FLX-KET promoted a higher
regrowth than IMP (P40.001) and FLX (P40.001; Figures 5m and
p). Exposure to uCMS induced an increase in dendritic length in
NAc medium spiny neurons (F6,28 = 24.73 Po0.001), and this
feature was reversed within all treatment groups (all Po0.01,
Figure 5a).
A signiﬁcant decrease in spine density (SD) was found in basal
(F6,28 = 22.11, Po0.001) and apical (F6,28 = 6.86, Po0.05) IL
dendrites of uCMS animals. Treatments with KET (Po0.001), IMP
(Po0.001), IMP-KET (Po0.001), FLX (Po0.001) and FLX-KET
(Po0.001) increased SD in IL basal dendrites; FLX-KET signiﬁcantly
increased SD in basal dendrites when compared with FLX alone
(F1,28 = 6.86, Po0.05). Treatment with FLX (Po0.001) and FLX-KET
(Po0.001) increased SD in apical dendrites. No signiﬁcant
increase of SD in apical dendrites was found in animals treated
with KET or IMP alone and in animals treated with IMP-KET.
Regarding spine morphology, mushroom spines are decreased in
uCMS animals both in apical (F6,28 = 5.712, Po0.001) and basal
(F6,28 = 2.668, Po0.001) dendrites when compared with control
animals. Treatment with KET (Po0.001), IMP-KET (Po0.001) and
FLX-KET (Po0.001) reverted this pattern in basal and apical IL
dendrites. No signiﬁcant increase in mushroom spine population
was found in animals treated with IMP or FLX alone; although the
treatment with IMP-KET and FLX-KET caused a signiﬁcant rise in
mushroom spine population in apical and basal dendrites when
compared with IMP (Po0.05) and FLX (Po0.01) alone (Figures 5e,
f, h and i).
Hippocampal dentate gyrus neurons in uCMS untreated animals
have signiﬁcant lower dendritic SD (F6,28 = 7.613, Po0.05) when
compared with control animals. Treatment with FLX (Po0.01) and
FLX-KET (Po0.01) signiﬁcantly increased SD. There was no
signiﬁcant increase in SD in animals treated with KET or IMP
alone or with IMP-KET. When evaluating the spine morphology,
speciﬁcally the more developed mushroom spines, uCMS animals
present also less number of mushroom dendritic spines in dentate
gyrus neurons (F6,28 = 8,162, Po0.05) (t= 5.267, Po0.001) but
treatment with KET (t= 5.477, Po0.001), IMP (t= 4.339, Po0.01),
IMP-KET (t= 5.903, Po0.001), FLX (t= 4.205, Po0.01) and FLX-KET
(t= 5.359, Po0.001) restored mushroom spines numbers (Figures
5k and l).
In the CA3, neurons from uCMS animals displayed a signiﬁcantly
lower dendritic SD in apical (F6,28 = 73.57, Po0.001) and basal
(F1,28 = 22.12, Po0.001) dendrites, which were recovered upon
treatment with all the tested drugs (Po0.001 to all). Addition of
KET to FLX treatment statistically increases spine density
(F1,28 = 6.86, Po0.05) in apical dendritic tree. The population of
mushroom dendritic spines is decreased in untreated uCMS
animals both in apical (F6,28 = 23.86, Po0.001) and basal
(F6,28 = 6.882, Po0.01) CA3 dendrites. In apical dendrites, treat-
ment with KET (Po0.001), IMP (Po0.05), IMP-KET (Po0.001) and
FLX-KET (Po0.001) caused an increase in mushroom spine
population. Both IMP-KET (Po0.01) and FLX-KET (Po0.001)
induce higher mushroom dendritic spine population. In basal
dendrites, treatment with KET (Po0.01), IMP-KET (Po0.01) and
FLX-KET (Po0.01) increased the amount of mushroom spines
(Figures 5n, o, q and r).
Exposure to uCMS induced a signiﬁcant increase in SD in
medium spiny neurons of the NAc (F6,28 = 7.297, Po0.01) and this
feature was reversed in the treatment with IMP, IMP-KET, FLX-KET
(Po0.01) and FLX (Po0.05). Regarding spine morphology, uCMS
promoted a decrease in the population of mushroom spines
(F6,28 = 9.094, Po0.001) and all treatments signiﬁcantly increase
mushroom spine compared with the untreated uCMS animals
(Po0.001). Importantly, the animals treated with antidepressant
and ketamine (IMP-KET and FLX-KET) presented a signiﬁcant
increase of mushroom spine population when compared with
those who were only given antidepressant (IMP or KET; Figures 5b
and c).
DISCUSSION
The use of KET in subanesthetic dose with antidepressant effect is
described both in animal models of stress and in MD
patients.13,24,25 Classic antidepressants are used with success in
our animal model, the uCMS.26 In our study, we aim to test the
effect of KET on the response of classic antidepressants. The effect
of KET alone is described in the literature, although there is a lack
of understanding regarding the synergetic effect of initial
antidepressant treatment with KET. Therefore, we propose to
investigate the effect of KET on the response of classic
antidepressants. In the literature, the methodology described for
the administration of KET is very heterogeneous; it goes from
Figure 5. Addiction of ketamine induces changes in neuronal dendritic morphology. In NAc medium spiny neurons: all treatment groups
restored decreased dendritic length (all Po0.01) (a); increase in SD in IMP, IMP-KET, FLX-KET (Po0.01) and FLX (Po0.05) treatment groups (b);
increase of MS population (IMP-KET and FLX-KET) compared with the animals given only antidepressant (IMP and KET) (c). IL apical dendrites
recover from decreased dendritic length (d). In IL apical dendrites, FLX (Po0.001) and FLX-KET (Po0.001) increased (e). IL basal dendrites,
treatment with IMP-KET (Po0.01), IMP (Po0,05) and FLX-KET (Po0,001) induced a reversion of dendritic shortening (g). In IL basal dendrites,
FLX-KET increased SD over FLX alone (h). Both IMP-KET and FLX-KET have increase in MS population in apical and basal dendrites when
compared with IMP (Po0.05) and FLX (Po0.01) alone (f and i). In DG hippocampal neurons: IMP-KET (Po0.001), IMP and FLX-KET (both
Po0.05) reverse the shortening in DG dendritic length (j); FLX and FLX-KET (Po0.001) increased SD (k); KET (Po0.001), IMP (Po0.01), IMP-
KET (Po0.001), FLX (Po0.01) and FLX-KET (Po0.001) restored MS (l). In hippocampal CA3 pyramidal neurons: KET (Po0.001), IMP-KET
(Po0.001) and FLX-KET (Po0.001) recovered basal dendritic length and FLX-KET produced increase in basal dendritic length compared with
FLX alone (Po0.01) (p); KET (Po0.05), IMP-KET (Po0.001), FLX (Po0.05) and FLX-KET (Po0.001) induced recovery in apical dendrites, both
IMP-KET and FLX-KET promoted a higher regrowth than IMP (P40.001) and FLX (P40.001) (m). Addition of KET to FLX treatment increases SD
(Po0.001) in apical dendritic tree (n) and KET (Po0.01), IMP-KET (Po0.01) and FLX-KET (Po0.01) increased the amount of MS (o); In CA3
basal dendrites all treated groups had a increase in SD (q); treatment with KET (Po0.001), IMP-KET (Po0.001) and FLX-KET (Po0.001)
produced an increase in MS and IMP-KET (Po0.01) and FLX-KET (Po0.001) induce higher MS population than IMP and FLX (r). DG, dentate
gyrus; FLX, ﬂuoxetine; IMP, imipramine; KET, ketamine; MS, mushroom spine; NAc, nucleus accumbens; SD, spinal density. Mean± s.e.m., n= 5,
*Po0.05; **Po0.01; ***Po0.001.
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single to multiple doses, the latest one given either daily or in
intermittent days. When designing the protocol of antidepressant
treatment we decided to use a multiple continuous method with a
short duration (3 days).
The SCT was used as a behavioral hallmark for recovery from
depressed phenotype. The ﬁrst evaluation occurred at the seventh
day of treatment and indicated that only animals treated with KET
(either alone or in combination with other antidepressant) display
behavioral rescue of anhedonia. After one additional week of
treatment, at the 14th day, all treated groups show reversion of
anhedonia, except the one only treated with KET, which showed a
reversion of the positive behavioral effect. In our results, we can
see the speciﬁc effect of the interaction of KET added to
antidepressant treatment on the results of the treated group
KET-FLX. The effect of KET alone in anhedonia does not last until
the 14th day, but when given with FLX, it enhances it.
The second hallmark of this model is learned helplessness, a
measure of behavior despair. There was an increase in latency to
immobility time in all treated animals but the analysis of total
immobility time shows that the effect of KET alone is not detected
2 weeks after being administrated. Again, when KET is given with
FLX, it is evident that there is an increase in latency time
compared with the antidepressant alone.
The analysis of anhedonia and despair in our model showed
that combining KET with other treatments seems to anticipate the
increase in sucrose preference and to improve the response. KET
possibly is acting as an initial booster and keeps the antidepres-
sant response. However, when given alone it failed to show a
robust result.
We also assessed anxiety and show that the combination of KET
with FLX or IMP was able to signiﬁcantly reverse the anxiety trait.
Again, there seems to be no anxiolytic effect after 2 weeks of KET
given alone. Some literature reports long-lasting anxyolitic effect
of KET given in a single dose to patients with depressive
disorders27 and in animal models when given in multiple
doses.28 However, we observed a positive effect when given with
antidepressants. When given together with the antidepressants,
beneﬁcial effect of KET extends beyond the mood domain and
also potentiates the anxiolytic effects of SSRIs and tricyclic
antidepressant drugs.
The positive effect of initial dual therapy with KET and other
antidepressant, concerning behavioral recovery in our animal
model, is a faster initial increase in sucrose preference and a more
robust response after 2 weeks of treatment not only in anhedonia
but also in behavioral despair and anxiety.
MD disorder and stress disorders have been associated with
impaired functional connectivity,29,30 as a result of dysfunction
occurring by several pathways. To evaluate the impact of KET in
neurotransmission, we have analyzed the levels of both GLU and
also we evaluated the dendritic architecture. We assessed the
levels of GLU in regions relevant for depressive-like behavior. Our
major ﬁnding was that NAc, a brain region implicated in
anhedonia,26,31 was the only region where KET, in association
with other antidepressants, triggered an increase in the levels of
GLU and ASP suggesting that this particular effect is ascribed to
GLU metabolism. The failure to observe signiﬁcant changes in GLU
or ASP levels in other brain regions probably relates to temporal
dynamics of the experimental design. However, literature reports
that both acute stressors and chronic stressors increase basal
release and increased presynaptic reuptake of GLU, but most
measurements were performed using mycrodialysis or synaptos-
somal analysis, thus reﬂecting extracellular contents, not the
overall content of GLU. There is evidence that KET acts as a
noncompetitive and nonselective high-afﬁnity NMDA antagonist
also on GABAergic neurons and may rapidly increase GLU release,
for example, in the PFC.32,33 Although there is clinical evidence
that treatment for depression increases the release of GLU in the
NAc,34 other studies using KET in individuals with MD were not
consistent in showing an association between therapy and
changes in neurotransmitter content.35,36 Present data suggest
changes in glutamatergic transmission, particularly in the NAc, a
mechanism through which KET helps restore mood.
Through the analysis of neuronal architecture, we conﬁrmed the
impact of uCMS on shrinkage of dendritic arborizations in the
hippocampus and in the IL area of the PFC, and dendritic
hypertrophy in NAc medium spiny neurons.7,8,26,37 Globally,
groups treated with antidepressant and KET showed a recovery
of the morphology of their dendritic trees, with a more consistent
response in FLX than IMP. Yet, the most striking changes were
noticed in dendritic spines; we not only found that the addition of
KET to the antidepressant treatment boosted a signiﬁcant
recovery in spine density when compared with antidepressants
alone, but also with greater spine maturation. KET is known to
have effects in synaptic plasticity: the fast-acting antidepressant
action of KET is known to be dependent on rapid protein synthesis
(namely of BDNF, PSD-95, GLuR1 and synapsin 1) and activation of
intracellular pathways such as mTOR, all of them physiologically
relevant for synaptic plasticity mechanisms, neuronal growth,
differentiation and synaptogenesis.38–41 Although the speciﬁc role
of mTOR in NAc is not fully understood in depression, the effect of
mTOR modulation is well studied in addiction. Therefore, we can
speculate the existence of some similarity between addiction
development and in antidepressant action. Indeed, the use of
rapamycin not only blocks establishment of addiction, but also the
antidepressant effect of KET.42 The acute and lasting effect of KET
in neuronal remodeling might be one of the reasons why it
improves behavioral markers of recovery in our experiment. The
particular case of combined treatment in increasing more mature
dendritic spine population shows that processes related to
synaptic functioning and rewiring have an important role in
behavioral recovery.
In summary, the present data show that KET has the potential to
improve the action of classic antidepressants in brain regions
affected by uCMS, a validated animal model of depression. The
addition of KET to antidepressants accelerate recovery from
anhedonia. The speciﬁc addition to FLX improves not only
anhedonia but also behavioral despair. Despite lack of robustness
in neurochemical data, we show improvement of glutamatergic
proﬁle in an area related to anhedonic behavior. The effects in
neuronal morphology show a potential mechanism for improve-
ment in synaptic connectivity in brain areas known to be affected
and responsible for behavioral hallmarks in MD. These results
show that KET has potential to improve the initial response of MD
treatment.
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